# China NMPA Drug Inspection - Hubei Qianjiang Pharmaceutical Co., Ltd. - Goose does not eat grass

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hubei-qianjiang-pharmaceutical-co-ltd/0a0e4ff0-1b9b-47a2-b016-30d7eb70f4a8/
Source feed: China

> China NMPA drug inspection for Hubei Qianjiang Pharmaceutical Co., Ltd. published October 31, 2019. Drug: Goose does not eat grass. This National Medical Products Administration (NMPA) announcement, published on October 31, 2019, details regulatory act

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement Regarding the Investigation and Handling of Substandard Chinese Medicinal Herbs
- Company Name: Hubei Qianjiang Pharmaceutical Co., Ltd.
- Publication Date: 2019-10-31
- Drug Name: Goose does not eat grass
- Inspection Finding: Impurities not meeting regulations constitute the sale of substandard drugs.
- Action Taken: An administrative penalty of a total fine of 330 yuan.
- Summary: This National Medical Products Administration (NMPA) announcement, published on October 31, 2019, details regulatory actions taken against two entities for issues involving unqualified Traditional Chinese Medicine materials. The first case concerned Ezhou Central Hospital, which on July 21, 2016, was found to be using substandard *Centipeda minima* (batch number 150401), supplied by Anhui People's Traditional Chinese Medicine Pieces Co., Ltd. The product contained impurities exceeding permitted levels, violating Article 49 of the Drug Administration Law. The Ezhou Municipal Food and Drug Administration imposed a fine and confiscated illegal gains totaling RMB 135.8. The second case involved Hubei Tianxiaming Pharmaceutical Co., Ltd., which on July 7, 2016, sold substandard *Centipeda minima* (batch number 150701), from Anhui Yishengyuan Traditional Chinese Medicine Pieces Technology Co., Ltd. This material also had impurities beyond regulatory limits, violating Article 49 of the Drug Administration Law. The Wuhan Municipal Food and Drug Administration issued an administrative penalty of RMB 330. These actions highlight strict enforcement of drug quality standards under China's drug administration laws.

Company: https://www.globalkeysolutions.net/companies/hubei-qianjiang-pharmaceutical-co-ltd/699fe3a9-41dd-437a-a8c7-d9fcf3559d46/